Subscribe Now Subscribe Today
Research Article
 

First Report of Pulmonary Nocardia transvalensis Infection from Turkey



Ozlem Mentes, Yasemin Zer , Iclal Balci and Mehmet Ozaslan
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Infections caused by Nocardia species have being reporting frequently in recent years. Nocardiosis usually occurs in patients who have either impaired local pulmonary defenses or systemic immuno-suppression. A 57 years old male patient with hemoptysis admitted to our hospital. Bronchoalveolar lavage and sputum specimen examined for mycobacteriae. BAL and sputum samples taken from the patient, the causal agent of this event isolated and determined as Nocardia transvalensis. An antimicrobial therapy with trimethoprim-sulfamethoxazole (TMP-SXT) 4 g/day started. At the end of the treatment clinic, radiologic and bacteriologic cure observed. This is the first report of pulmonary N. transvalensis infection from Turkey.

Services
Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Ozlem Mentes, Yasemin Zer , Iclal Balci and Mehmet Ozaslan , 2006. First Report of Pulmonary Nocardia transvalensis Infection from Turkey. Pakistan Journal of Biological Sciences, 9: 2384-2386.

DOI: 10.3923/pjbs.2006.2384.2386

URL: https://scialert.net/abstract/?doi=pjbs.2006.2384.2386

INTRODUCTION

Nocardia firstly described by Edmund Nocard in 1888 (Lederman et al., 2004). Members of the genus Nocardia are aerobic actinomycetes that are ubiguitous saprophytes in soil, decaying organic matter and water (Karaaslan, 1999; Matulionyte et al., 2004; Carriere et al., 1999; Dikensoy et al., 2004). When observed microscopically, either gram stains of clinical specimens, cultures or when histopathologically in tissues Nocardia are branching, beaded, filamentous, gram positive bacteria and are usually weakly acid-fast (Karaaslan, 1999; Saubolle and Sussland, 2003). Nocardia species are responsible for a wide spectrum of disease in patients with both normal and abnormal immune systems (Lederman et al., 2004). In general, nocardiosis is a disease that affects primarily the cell-or humorally immuno-compromised population: transplant recipients, patients on high dose steroid and patients with cancer, AIDS or other leucocyte deficiencies, diabetes mellitus, SLE, sarcoidosis, cystic fibrosis, emphysema, asthma, bronchiectasis, tuberculosis and alveolar proteinosis (Lederman et al., 2004; Saubolle and Sussland, 2003; Menendez et al., 1997). The authors estimate that less than 10% of patients with nocardiosis have no definable underlying predisposing factors (Saubolle and Sussland, 2003). Most infections in humans are due to N. asteroides group (Lederman et al., 2004; Beaman and Beaman, 1994). Species like N. brasiliensis, N. nova, N. farcinica, N. transvalensis, N. africana are also isolating in growing frequencies (Saubolle and Sussland, 2003). N. asteroides usually causes pulmonary infections. The form in the lung is developing because of inhalation of sports. (Menendez et al., 1997). N. transvalensis, a rare nocardia species previously been recognized as cause of actinomycotic mycetoma (MC Neil et al., 1992; Lopez et al., 2003). Nocardiosis is the most commonly seen in the age group 20-60 and affects men and women equally (Philip 1996). Nocardial infections are not thought to be transmitted from person to person and are usually acquired nosocomically (Saubolle and Sussland, 2003; Menendez et al., 1997). A sharp increase in nocardiosis infections are reported from throughout the world since 1960 (Menendez et al., 1997). We exactly do not know reasons for this, but the idea, related to the development of new diagnostic methods, prevalence of transplantation applications and immuno-suppressive treatment usage. Earlier reports estimated that 500 to 1000 cases/year occur in USA and probably 150-250 in France (Matulionyte et al., 2004; Menendez et al., 1997).

Case report: A 57 years old male patient admitted to Gaziantep University Hospital Cardio-vascular surgery department because of complaint of hemoptysis for 7 months and 3 times a day for last ten days. Patient used to smoke one pocket of cigarette per day over twenty years. Physical examination of the chest common rates observed. Examination of the other systems was unremarkable. Admission in laboratory values were as follows: WBC 6.98x103 μL–1, hemoglobin 15.3 g dL–1, hematocrit 45.2%, erythrocyte sedimentation rate 33 mm h–1, BUN 56 mg dL–1 (normal range 10-50 mg dL–1), glucose 70 mg dL–1 (normal range 70-110 mg dL–1), albumin 4.8 g dL–1 (normal range 3.4-5.5 g dL–1), CRP 6.1 mg dL–1 (normal range 0-5 mg dL–1). In CT examination of lungs, chronic infiltrations, fibrotic changes and bronchiectasis observed. In the left lung, lower lobar cavitations with 30 mm in diameter and fibrotic sequel in the two upper both of lobar also observed. Diagnostic bronchoscopy applied to patient and brochoalveolar lavage taken and sent to our laboratory for mycobacterial culture.

MATERIALS AND METHODS

After the decontamination and homogenization of the sample (BAL), in EZN stain, acid-fast bacteria observed. Sample inoculated onto BACTEC (Becton Dickinson, USA) middlebrook 7H12 medium test tubes for mycobacterial culture. After no increase in growth index observed for 10 days, the BAL sample inoculated to SDA and 5% sheep blood agar medium from test tubes. After incubation for 72 h in blood agar medium white, R type, harsh, embedded to medium, velvety colonies produced (Fig. 1). Gram stain performed to colonies and gram positive, filamentous, branching bacteria observed.

Image for - First Report of Pulmonary Nocardia transvalensis Infection from Turkey
Fig. 1: Nocardia transvalensis bacterial growth in blood agar medium

Modified EZN stain (decolorized by 1% sulfuric acid instead of acid-alcohol) applied to colonies and acid-fast bacteria observed. Urea test was positive, so, isolate evaluated as Nocardia sp. BAL and sputum samples taken from the same patient after 15 days of first isolation. The same bacterium determined again. Isolated bacteria sent to reference laboratory (Faculte De Pharmacie, Laboratorie De Mycologie, Lyon, France) by Turkish Microbiology Society Nocardiosis Work Group for further tests on identifying species and antibiotic sensitivity.

RESULTS

The isolate identified as Nocardia transvalensis. As the antibiotic test results: the isolate susceptible to cefotaxime, ceftriaxsone, cefepime, amikacin, minocyclin, amoxicillin clavulanic acid, TMP-SXT, it was intermediately susceptible to amoxicillin, piperacillin-tazobactam and imipenem and resistant to ampicillin, ticarcillin, piperacillin, gentamycin, tobramycin, erythromycin, vankomycin, trimethoprim and rifampicin. Therapy with TMP-SXT (4 g/day) started for six months. After 4 weeks in the first control, there was no complaint about hemoptysis but radiological findings still were visible. The work on the mycobacteriae through the bronchoalveolar lavage which taken in the beginning continued till 6 weeks then the results was negative against to mycobacteriae. It indicated that the causal organism of the patient is not related with tuberculosis.

DISCUSSION

Nocardiosis is usually an opportunistic infection and most commonly presents as pulmonary disease (Saubolle and Sussland, 2003). The majority of patients with clinically recognized disease have underlying debilitating factors. Depressed immune system especially T cells and macrophages is an important predisposing factor in nocardia infections. T cells and macrophages kill the bacteria and prevent dissemination (Matulionyte et al., 2004; Menendez et al., 1997; Beaman and Beaman, 1994). So observing opportunistic infections in immunosuppressive patients is not a surprise. Hui et al. (2003) have retrospectively reviewed 35 patients with pulmonary nocardiosis. They reported that the majority (63%) of them have had an underlying respiratory disorder ranging from common conditions such as chronic obstructive lung disease (26%), asthma and bronchiectasis (20%), to less common ones such as previous tuberculosis and cystic fibrosis (5.7%). Non-respiratory disorders were comprised of patients with underlying malignancies (20%), organ transplantation (8.6%), autoimmune disorders (5.7%) and HIV (5.7%). Pulmonary nocardiosis clinically causes cough (with or without hemoptysis), anorexia, fever, weight loss and dyspnea (Philip, 1996). Radiological signs are not specific too. Serologic diagnosis is unreliable and serologic tests are not available commercially. Gram staining is the most sensitive method by which to visualize and recognize nocardia in clinical specimens (Saubolle and Sussland, 2003).

Nocardia normally appears with 2 to 7 days on most routine bacteriologic media such as sheep blood agar, chocolate agar and BACTEC blood culture broth media. Nocardia are rarely seen as contaminants in the laboratory and each isolate must be carefully evaluated as to its clinical significance (Saubolle and Sussland, 2003). Clinically, it may mimic a carcinoma, tuberculosis or other granulomatous diseases of the lung (Singh et al., 2000).

In this case, hemoptysis was the only symptom. There was no history of drug usage, which could depress the immune system. Nonetheless, it is a great possibility that bronchiectasis may be the underlying factor for pulmonary nocardiosis (Hui et al., 2003). TMP-SXT was used for 6 months. After treatment sputum sample was taken from patient but no pathogen was grown on culture. Then the control CT taken and it is revealed that no more cavitation present in lung.

As a conclusion of this study work, the tests for identification of bacteria, in particular Nocardia spp. must not neglected in the risk group of pulmonary or systemic diseases.

REFERENCES

  1. Beaman, B.L. and L. Beaman, 1994. Nocardia sp. Host-parasite relationships. Clin. Mic. Rev., 7: 213-264.
    Direct Link  |  


  2. Carriere, C., H. Marchandin, J.M. Andrieu, A. Vandome and C. Perez, 1999. Nocardia thyroiditis unusual location of infection. J. Clin. Microbiol., 37: 2323-2325.
    Direct Link  |  


  3. Dikensoy, O., A. Filiz, N. Bayram, I. Balci and Y. Zer et al., 2004. First report of pulmonary Nocardia otitidiscaviarum infection in an immunocompetent patient from Turkey. Int. J. Clin. Practice, 58: 210-213.
    Direct Link  |  


  4. Hui, C.H., V.W. Au, K. Rowland, J.P. Slavotinek and D.L. Gordan, 2003. Pulmonary nocardiosis revisited experience of 35 patients at diagnosis. Respir. Med., 97: 709-717.


  5. Karaaslan, A., 1999. Nocardia. In: Temel ve Klinik Mikrobiyoloji, Ustacelebi, O. (Ed.). Guneo kitapevi Ltd., Ankara, pp: 463-469


  6. Lederman, E.R., M.C. Nancy and F.N.R.A. Crum, 2004. Case series and focused review of nocardiosis. Clin. Micribiol. Aaspects Med., 83: 300-313.
    PubMed  |  Direct Link  |  


  7. Lopez, F.A., F. Johnson, D.M. Novasad, B.L. Beaman and M. Holodniy, 2003. Successful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development sulfonamid resistance case report and review. J. Heart Lung Transplant, 4: 492-497.
    Direct Link  |  


  8. Matulionyte, R., P. Rohner, I. Uckay, D. Lew and J. Garbino, 2004. Seculary trends of nocardia infection over 15 years in a tertiary care hospital. J. Clin. Pathol., 57: 807-812.
    CrossRef  |  


  9. Mc Neil, M.M., J.M. Brown, P.R. Georghiou, A.M. Allworth and Z.M. Blacklock, 1992. Infections due to Nocardia transvalensis Clinical spectrum and antimicrobial therapy. Clin. Infect. Dis., 15: 453-463.
    PubMed  |  Direct Link  |  


  10. Menendez, R., P.J. Cordero, M. Santos, M. Gobernado and V. Marco, 1997. Pulmonary infection with Nocardia species a report of 10 cases. Eur. Respir. J., 10: 1542-1546.
    Direct Link  |  


  11. Philip, L., 1996. Nocardiosis. Clin. Inf. Dis., 22: 891-905.


  12. Saubolle, M.A. and D. Sussland, 2003. Nocardiosis review of clinical and laboratory experience. J. Clin. Microbiol., 41: 4497-4501.


  13. Singh, M., R.S. Sandhu, H.S. Randhawa and B.M.K., 2000. Prevalence of pulmonary nocardiosis in a tuberculosis amritsar punjab. Ind. J. Chest Dis. Allied Sci., 42: 325-339.
    Direct Link  |  


©  2022 Science Alert. All Rights Reserved